S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Russia Ignites West's Battle for Energy Independence (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Big climate bill: Spending green bucks to spur green energy
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Russia Ignites West's Battle for Energy Independence (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Big climate bill: Spending green bucks to spur green energy
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Russia Ignites West's Battle for Energy Independence (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Big climate bill: Spending green bucks to spur green energy
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Russia Ignites West's Battle for Energy Independence (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Big climate bill: Spending green bucks to spur green energy
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
NASDAQ:AMGN

Amgen - AMGN Stock Forecast, Price & News

$248.35
-3.74 (-1.48%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$247.99
$253.36
50-Day Range
$230.71
$252.09
52-Week Range
$198.64
$258.45
Volume
2.69 million shs
Average Volume
2.45 million shs
Market Capitalization
$132.85 billion
P/E Ratio
21.05
Dividend Yield
3.08%
Price Target
$245.14

Amgen MarketRank™ Forecast

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
1.3% Downside
$245.14 Price Target
Short Interest
Healthy
3.24% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
0.19mentions of Amgen in the last 14 days
Based on 51 Articles This Week
Insider Trading
Selling Shares
$150,000 Sold Last Quarter
Proj. Earnings Growth
9.93%
From $17.42 to $19.15 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

86th out of 1,112 stocks

Biological Products, Except Diagnostic Industry

11th out of 175 stocks

AMGN stock logo

About Amgen (NASDAQ:AMGN) Stock

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. SVB Leerink assumed coverage on shares of Amgen in a research report on Monday, May 23rd. They set a "market perform" rating and a $256.00 price objective for the company. Royal Bank of Canada upped their price objective on shares of Amgen from $224.00 to $236.00 in a research report on Friday, August 5th. StockNews.com cut shares of Amgen from a "strong-buy" rating to a "buy" rating in a research report on Monday. BMO Capital Markets cut their price objective on shares of Amgen from $263.00 to $243.00 in a research report on Thursday, April 28th. Finally, Morgan Stanley upped their price objective on shares of Amgen from $239.00 to $253.00 and gave the stock an "equal weight" rating in a research report on Friday, July 15th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $245.14.

Amgen Stock Performance

Amgen stock opened at $248.35 on Friday. The business has a 50 day moving average of $244.78 and a 200-day moving average of $240.25. Amgen has a 1 year low of $198.64 and a 1 year high of $258.45. The company has a debt-to-equity ratio of 14.76, a current ratio of 1.53 and a quick ratio of 1.17. The company has a market capitalization of $132.85 billion, a P/E ratio of 21.05, a P/E/G ratio of 2.01 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The medical research company reported $4.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.25. Amgen had a return on equity of 218.34% and a net margin of 24.92%. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.53 billion. During the same quarter in the prior year, the firm posted $4.38 earnings per share. The firm's revenue was up 1.0% compared to the same quarter last year. On average, equities research analysts predict that Amgen will post 17.42 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 8th. Stockholders of record on Thursday, August 18th will be paid a $1.94 dividend. This represents a $7.76 annualized dividend and a dividend yield of 3.12%. The ex-dividend date is Wednesday, August 17th. Amgen's dividend payout ratio is currently 65.76%.

Insider Activity

In other news, Director R Sanders Williams sold 600 shares of the company's stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $250.00, for a total value of $150,000.00. Following the completion of the transaction, the director now owns 5,501 shares of the company's stock, valued at $1,375,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.46% of the stock is currently owned by insiders.

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Stock News Headlines

Two Appealing Biotech Stocks for Two Distinct investors (AMGN)
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
Should You Buy AbbVie Ahead Of Earnings? (AMGN)
AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?
Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
Amgen (NASDAQ:AMGN) Stock Rating Reaffirmed by Oppenheimer
Amgen (NASDAQ:AMGN) Rating Lowered to Buy at StockNews.com
Russia Ignites West's Battle for Energy Independence
Putin's invasion of Ukraine has revealed the West's dependence on Russia for their energy needs. Western countries are now scrambling for stable, renewable energy. World leaders must find new sources of minerals, such as copper, essential to their transition to energy independence.
Analyst Ratings for Amgen
Analyst Ratings for Amgen - Benzinga
What Are Whales Doing With Amgen - Benzinga
Why ChemoCentryx Stock Is On Fire Today
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
AMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Company Calendar

Ex-Dividend for 6/8 Dividend
5/16/2022
Dividend Payable
6/08/2022
Last Earnings
8/04/2022
Today
8/12/2022
Ex-Dividend for 9/8 Dividend
8/17/2022
Dividend Payable
9/08/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
24,200
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$245.14
High Stock Price Forecast
$290.00
Low Stock Price Forecast
$182.00
Forecasted Upside/Downside
-1.3%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
16 Analysts

Profitability

Net Income
$5.89 billion
Pretax Margin
28.40%

Debt

Sales & Book Value

Annual Sales
$25.98 billion
Cash Flow
$23.28 per share
Book Value
$4.52 per share

Miscellaneous

Free Float
532,470,000
Market Cap
$132.85 billion
Optionable
Optionable
Beta
0.56

Social Links


Key Executives














AMGN Stock - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings
or view top-rated stocks.

What is Amgen's stock price forecast for 2022?

16 analysts have issued 12 month price targets for Amgen's shares. Their AMGN share price forecasts range from $182.00 to $290.00. On average, they expect the company's stock price to reach $245.14 in the next twelve months. This suggests that the stock has a possible downside of 1.3%.
View analysts price targets for AMGN
or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2022?

Amgen's stock was trading at $224.97 at the beginning of 2022. Since then, AMGN stock has increased by 10.4% and is now trading at $248.35.
View the best growth stocks for 2022 here
.

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our AMGN earnings forecast
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) released its earnings results on Thursday, August, 4th. The medical research company reported $4.65 EPS for the quarter, beating analysts' consensus estimates of $4.40 by $0.25. The medical research company earned $6.59 billion during the quarter, compared to the consensus estimate of $6.53 billion. Amgen had a trailing twelve-month return on equity of 218.34% and a net margin of 24.92%. The firm's revenue was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.38 EPS.
Read the conference call transcript
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Wednesday, August 3rd. Investors of record on Thursday, August 18th will be given a dividend of $1.94 per share on Thursday, September 8th. This represents a $7.76 annualized dividend and a dividend yield of 3.12%. The ex-dividend date is Wednesday, August 17th.
Read our dividend analysis for AMGN
.

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $7.76 per share and currently has a dividend yield of 3.08%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 65.76%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 40.52% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2022 earnings guidance on Thursday, August, 11th. The company provided earnings per share (EPS) guidance of $17.00-$18.00 for the period, compared to the consensus EPS estimate of $17.40. The company issued revenue guidance of $25.50 billion-$26.40 billion, compared to the consensus revenue estimate of $26.23 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (2.92%), Deutsche Bank AG (0.91%), State Farm Mutual Automobile Insurance Co. (0.52%), California Public Employees Retirement System (0.45%), Swiss National Bank (0.45%) and Sumitomo Mitsui Trust Holdings Inc. (0.36%). Insiders that own company stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends
.

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $248.35.

How much money does Amgen make?

Amgen (NASDAQ:AMGN) has a market capitalization of $132.85 billion and generates $25.98 billion in revenue each year. The medical research company earns $5.89 billion in net income (profit) each year or $11.80 on an earnings per share basis.

How many employees does Amgen have?

The company employs 24,200 workers across the globe.

Does Amgen have any subsidiaries?

The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More

When was Amgen founded?

Amgen was founded in 1980.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.

This page (NASDAQ:AMGN) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.